secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALLURION TECHNOLOGIES, INC. (ALUR)
CIK:        0001964979
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001193125-25-031990
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allurion raises ~$6.1M via registered direct offering and private placement to fund GLP-1 clinical pipeline
--------------------------------------------------------------------------------

- Issued 900,000 shares of common stock at $5.23/share and 1,800,000 warrants (exercise $5.23, 5-year term, exercisable only after stockholder approval).
- Also issued 267,686 shares and 535,372 warrants to Leavitt Equity Partners at $5.23/share in a concurrent private placement.
- Total gross proceeds expected to be ~$6.1M; net proceeds will fund muscle mass/GLP-1 adherence trials, working capital, and general corporate purposes.
- As consideration, company will seek stockholder approval to reduce exercise price of Leavitt’s July 2024 warrants from $30.00 to $6.00 per share.
- Offering closed on February 20, 2025; Roth Capital Partners acted as exclusive placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964979/000119312525031990/0001193125-25-031990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964979/000119312525031990/d924898d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-031990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer